Less than twenty years ago photolithography and medicine were total strangers to one another. They had not yet met, and not even looking each other up in the classifieds. And then, nucleic acid chips, microfluidics and microarrays entered the scene, and rapidly these strangers became indispensable partners in biomedicine. As recently as ten years ago the notion of applying nanotechnology to the fight against dis- ease was dominantly the province of the fiction writers. Thoughts of nanoparticle-vehicled delivery of therapeuticals to diseased siteswere an exercise in scientific solitude, and grounds for questioning one’s ability to think “like an established scientist”. And today we have nanoparticulate paclitaxel as the.
